Group 1 - The National Drug Administration of China announced that by 2025, the country is expected to approve 76 innovative drugs, ranking first globally [2] - The approval process reforms have effectively stimulated innovation in the pharmaceutical industry, leading to a projected total transaction volume of over $130 billion for Chinese innovative drug BD (business development) overseas licensing in the same year [2] - The Hong Kong Stock Connect Innovative Drug Index (987018) showed strong performance with significant gains in constituent stocks, indicating positive market sentiment towards innovative pharmaceuticals [1] Group 2 - Positive clinical data for small nucleic acid drugs has been reported, with ongoing optimism for the innovative drug sector [2] - Arrowhead Pharmaceuticals released mid-term data for ARO-INHBE and ARO-ALK7, demonstrating efficacy in patients with T2D obesity, which enhances market confidence in small nucleic acids for weight management [2] - The recent listing of Reborna Bio on the Hong Kong Stock Exchange has seen active stock performance, with its core pipeline targeting thrombotic diseases, indicating a promising market potential exceeding $50 billion [2]

Group 1 - The Hong Kong Innovation Drug Index (987018) has seen a strong increase of 2.33% as of May 21, 2025, with notable gains in constituent stocks such as CanSino Biologics (06185) up 8.87%, Junshi Biosciences (01877) up 8.16%, and Kelun Pharmaceutical (06821) up 7.02% [1] - The Hong Kong Innovation Drug ETF (159567) has risen by 1.56%, marking its fourth consecutive increase, with the latest price reported at 1.3 HKD. Over the past week, the ETF has accumulated an increase of 8.63% [1] - The trading activity for the Hong Kong Innovation Drug ETF has been robust, with an intraday turnover of 10.03% and a transaction volume of 171 million HKD, indicating active market participation. The average daily trading volume over the past month reached 736 million HKD, with the ETF's latest scale reaching 1.667 billion HKD, a new high in nearly a year [1] Group 2 - The CDMO sector is expected to see rapid growth driven by the increasing demand for chemical macromolecules and XDC CDMO production, particularly in polypeptides and oligonucleotides, presenting investment opportunities in the related industry chain [1] - The CRO sector is anticipated to benefit from improving overseas financing conditions and a gradual shift towards a rate-cutting environment, with expectations of revenue recovery for integrated CRO/CDMO and domestic preclinical CROs, suggesting potential valuation recovery opportunities [2] - The CRO sector has been significantly impacted by domestic and international financing challenges, but with supportive domestic policies, there is an expectation for gradual recovery, highlighting investment opportunities in clinical CROs [2]